Boston Scientific's second quarter was shaped by healthy growth in its Interventional Cardiology, Endoscopy, and Neuromodulation businesses, which counterbalanced notable slowdowns in ...

An Alabama woman sued Boston Scientific and Boston Scientific Neuromodulation, alleging one of the companies’ spinal cord stimulator systems caused injuries after it was implanted to treat chronic ...

Boston Scientific is taking clear steps to advance its European, Middle East and Africa (EMEA) region market position in the urology space. The company drew significant attention at the J.P. Morgan ...

Boston Scientific’s BSX Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. This segment reflects the company’s ...

Boston Scientific Corp (BSX) reports a robust Q2 with 7% organic sales growth and a 15% increase in adjusted EPS, despite challenges in some segments.

Boston Scientific is growing its urology portfolio with a $3.7 billion deal to acquire Axonics, makers of neurostimulation therapies for urinary and fecal incontinence. Currently a chief competitor in ...

EP/WATCHMAN slowdown drives discount valuation. See why it’s a Buy—new launches, insider buying, cost savings.

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Medical device maker Boston Scientific said on Monday it had agreed to buy Axonics for $3.7 billion, gaining access to devices used to improve bladder function. The deal marks Boston Scientific's ...